Technical Analysis for KURA - Kura Oncology, Inc.

Grade Last Price % Change Price Change
grade D 15.96 3.03% 0.47
KURA closed up 3.03 percent on Monday, March 18, 2019, on 58 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical KURA trend table...

Date Alert Name Type % Chg
Mar 18 50 DMA Support Bullish 0.00%
Mar 18 180 Bullish Setup Bullish Swing Setup 0.00%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 18 Weak + Overbought Other 0.00%
Mar 18 BB Squeeze Ended Range Expansion 0.00%
Mar 18 Outside Day Range Expansion 0.00%
Mar 18 Overbought Stochastic Strength 0.00%
Mar 15 Stochastic Sell Signal Bearish 3.03%
Mar 15 Bollinger Band Squeeze Range Contraction 3.03%
Mar 15 Weak + Overbought Other 3.03%

Older signals for KURA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule drug candidates that target cell signaling pathways, which drive the progression of various cancers. The company's lead drug candidate, tipifarnib, an inhibitor of protein farnesylation is in Phase II clinical trials used for the treatment of solid tumors, including thyroid, head, neck, urothelial carcinomas, and salivary cancers with HRAS mutations, as well as patients with peripheral T-cell lymphoma. Its product pipeline also comprise preclinical programs, such as orally-available small molecule inhibitors of extracellular-signal-regulated kinases 1 and 2, such as KO-947 and other backup compounds for the treatment of patients with activating mutations in or other dysregulation of the mitogen-activated protein kinase signaling pathway consisting of mutations in KRAS, BRAF, and NRAS; and orally available, small molecule inhibitors of the menin-MLL interaction for the treatment of patients with acute leukemias involving translocations or partial tandem duplications of the mixed lineage leukemia (MLL) gene. The company was founded in 2014 and is headquartered in La Jolla, California.
Medicine Cancer Solid Tumors Oncology Cancers Cell Signaling Oncogenes Signal Transduction Benzamides Ras Subfamily Binimetinib Blood Cancers Braf Kras Mek Inhibitor
Is KURA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 22.0
52 Week Low 10.2
Average Volume 219,059
200-Day Moving Average 16.1335
50-Day Moving Average 15.382
20-Day Moving Average 15.179
10-Day Moving Average 15.175
Average True Range 0.7627
ADX 10.82
+DI 20.1826
-DI 17.6575
Chandelier Exit (Long, 3 ATRs ) 13.7419
Chandelier Exit (Short, 3 ATRs ) 15.6081
Upper Bollinger Band 16.1693
Lower Bollinger Band 14.1887
Percent B (%b) 0.89
BandWidth 13.04829
MACD Line 0.1688
MACD Signal Line 0.0599
MACD Histogram 0.1089
Fundamentals Value
Market Cap 319 Million
Num Shares 20 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -10.43
Price-to-Sales 0.00
Price-to-Book 6.41
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.05
Resistance 3 (R3) 16.95 16.48 16.87
Resistance 2 (R2) 16.48 16.21 16.53 16.81
Resistance 1 (R1) 16.22 16.04 16.35 16.32 16.75
Pivot Point 15.76 15.76 15.82 15.81 15.76
Support 1 (S1) 15.50 15.48 15.63 15.60 15.17
Support 2 (S2) 15.03 15.31 15.08 15.11
Support 3 (S3) 14.77 15.03 15.05
Support 4 (S4) 14.87